Skip to main content

MCL-RI Information & Policies

A reference page for active Mantle Cell Lymphoma Research Initiative (MCL-RI) grantees

For information about other programs, click here.

For information about applying for LLS research funding, click here.

Grant Requirements

Reporting Schedule: Progress, IP Disclosure, and Financial Reports are required for each year of the grant, and Publications Reports are required each quarter. The reporting schedule for your particular grant is printed on your Grant Agreement. This schedule is also available under Reports Due in the LLS Research Portal (FLUXX).
Below is an example of a typical schedule for an MCL-RI grant that began January 1, 2018.

Example Reporting Schedule for MCL-RI

Publications Report #1

July 1, 2018

Publications Report #2

  October 1, 2018

Publications Report #3

January 1, 2019

Interim Year 1 Progress Report
Interim Year 1 IP Disclosure Report*
Interim Year 1 Financial Report

  March 1, 2019

Publications Report #4

  April 1, 2019

Publications Report #5

  July 1, 2019

Publications Report #6

  October 1, 2019

Publications Report #7

  January 1, 2020

Interim Year 2 Progress Report
Interim Year 2 IP Disclosure Report*
Interim Year 2 Financial Report

  March 1, 2020

Publications Report #8

  April 1, 2020

Publications Report #9

  July 1, 2020

Publications Report #10

  October 1, 2020

Publications Report #11

  January 1, 2021

Interim Year 3 Progress Report
Interim Year 3 IP Disclosure Report*
Interim Year 3 Financial Report

March 1, 2021

Publications Report #12

  April 1, 2021

Publications Report #13

July 1, 2021

Publications Report #14

October 1, 2021

Publications Report #15

January 1, 2022

Interim Year 4 Progress Report
Interim Year 4 IP Disclosure Report*
Interim Year 4 Financial Report

March 1, 2022

Publications Report #16

April 1, 2022

Publications Report #17

July 1, 2022

Publications Report #18

October 1, 2022

Publications Report #19

January 1, 2023

Final Progress Report
Final IP Disclosure Report*
Final Financial Report

March 1, 2023

*The IP Disclosure Report was formerly referred to as the Patent Report.

Report Submission: LLS research grant reporting is conducted through the LLS Research Portal (FLUXX). Access this portal using the same username and password that were used during the application process. 
Individuals responsible for submitting reports must be manually added to each individual grant record in our system in order for them to have reporting access for each grant. Contact to update reporting access for your grant.

Progress Reports and Publications Reports should be submitted by the researcher (the PI). Financial Reports should be submitted by the financial officer, and IP Disclosure Reports should be submitted by the technology/transfer officer. 

The Progress Report and IP Disclosure Report submissions must include one report for each participating Project and Core.

Researchers and administrators should be careful to follow all instructions on the report web form and downloadable template. Reports that fail to follow instructions will be returned for revision, which may delay grant payment. Do not save templates for future use; the templates are subject to change and therefore must be newly downloaded for each submission.

Click here to download the Report Submission Guide for detailed instructions on submitting a report in the LLS Research Portal (FLUXX).
Note: FLUXX recently updated the grantee portal view, so the pages will visually be different from the screenshots shown in this guide. This change is aesthetic only; the process for submitting reports remains unchanged.

Annual Site Visit: Site Visits will occur around the anniversary of the grant start date for each year of the grant period. The MCL-RI Progress Review Committee, consisting of LLS Research staff and external reviewers, will visit the MCL-RI Director and members of the team. The MCL-RI Director, Project Leaders and Core Leaders must be present. The MCL-RI team will present an overview of the progress made within the last year in relation to the aims of the MCL-RI and the milestones/deliverables agreed upon the year before. Any problems encountered should be discussed, and any changes from the original aims should be justified. 

Grant Payment

LLS pays research grants quarterly in March, June, September, and December. Payments are contingent upon reporting requirements; all report approvals must be up to date in order for payment to be processed. A list of sent payments can be viewed in the LLS Research Portal (FLUXX) under Dispersed Payments.



If the MCL-RI Director leaves the institution to which the award is made or is unable to conduct the leadership expected, LLS must be notified immediately, and LLS may, at its sole discretion in that circumstance, terminate funding of the MCL-RI grant within thirty (30) days of the incapacity or departure of the grantee. If a research Project or scientific Core leader leaves the institution or is incapacitated, LLS must be notified immediately. The Sponsoring Institution and/or MCL-RI Director must inform LLS of actions to be taken to replace the Project/Core leader so as to maintain the Project/Core. LLS shall have the prerogative to suspend funding for the MCL-RI within thirty (30) days after notification should a resolution satisfactory to LLS not be proposed.

If a leader of a Project or a Core intends to move to a new institution during the course of the MCL-RI grant term and the MCL-RI Director feels that continued collaboration is desirable and possible, the MCL-RI Director or Sponsoring Institution must submit to a detailed explanation and justification for continued participation by the Project/Core leader. This request must have the approval of the institution at which the Center resides and the new institution to which the leader of the Project/Core is moving. LLS will retain the right to discontinue funding for the MCL-RI within thirty (30) days after departure of a Project or Core leader if arrangements acceptable to LLS are not established.


Leaves of Absence

During the five-year term of the grant, MCL-RI Directors may not be absent from the  Sponsoring Institution. Project or Core leaders, likewise, may not be absent from their original participating institution during the five-year term of the grant. If unavoidable, an absence greater than 30 days requires prior written permission from LLS. If a grant is interrupted, LLS must be notified promptly. Written permission must be obtained from LLS for the grant to be continued at a later date. In the event a grant is not completed due to incapacitating illness or death of the grantee/MCL-RI Director, the prorated, unexpended funds must be returned to LLS.


No-Cost Extensions

MCL-RI grantees are permitted to request a no-cost extension for a maximum of one year in duration. At the end of the no-cost extension period, any funds remaining must be returned to LLS. To request a no-cost extension, complete a Special Requests report in the LLS Research Portal (FLUXX). If the request is approved, the grant period will be extended for one year, and final reports will be due 60 days following the new end date. The final payment will be paid once final reports are received and approved by LLS.

If you have questions regarding your grant that are not addressed here, please contact the Research Administration Team at